Q3 Earnings Alert: These are the most overvalued right nowSee Overvalued Stocks

Apple wins $250 US jury verdict in patent case over Masimo smartwatches

Published 26/10/2024, 09:20 am
© Reuters. FILE PHOTO: The Apple Watch Ultra 2 is showcased as Apple holds an event at the Steve Jobs Theater on its campus in Cupertino, California, U.S. September 9, 2024. REUTERS/Manuel Orbegozo/File Photo
AAPL
-

By Blake Brittain

(Reuters) -Apple convinced a federal jury on Friday that early versions of health monitoring tech company Masimo's smartwatches infringe two of its design patents as part of a broader intellectual property dispute between the companies.

The jury, in Delaware, agreed with Apple (NASDAQ:AAPL) that previous iterations of Masimo's W1 and Freedom watches and chargers willfully violated Apple's patent rights in smartwatch designs.

But the jury awarded the tech giant, which is worth about $3.5 trillion, just $250 in damages - the statutory minimum for infringement in the United States.

Apple's attorneys told the court the "ultimate purpose" of its lawsuit was not money, but to win an injunction against sales of Masimo's smartwatches after an infringement ruling.

On that front, jury also determined that Masimo's current watches did not infringe Apple patents covering inventions that the tech giant had accused Masimo of copying.

Masimo said in a statement it appreciated the jury's verdict "in favor of Masimo and against Apple on nearly all issues," and that the decision only applied to a "discontinued module and charger."

"Apple primarily sought an injunction against Masimo's current products, and the jury's verdict is a victory for Masimo on that issue," Masimo said.

Apple said in a statement that it was "glad the jury's decision today will protect the innovations we advance on behalf of our customers."

Irvine, California-based Masimo accused Apple of hiring away its employees and stealing its pulse oximetry technology after discussing a potential collaboration.

Masimo convinced the U.S. International Trade Commission last year to block imports of Apple's Series 9 and Ultra 2 smartwatches after the commission found their technology for reading blood oxygen levels infringed Masimo's patents.

Apple has appealed the decision and resumed selling the watches after removing the technology. The tech giant countersued Masimo for patent infringement in 2022, alleging Masimo copied Apple Watch features to use in its smartwatches.

© Reuters. FILE PHOTO: The Apple Watch Ultra 2 is showcased as Apple holds an event at the Steve Jobs Theater on its campus in Cupertino, California, U.S. September 9, 2024. REUTERS/Manuel Orbegozo/File Photo

Apple also accused Masimo of using lawsuits at the ITC and in California to "make way for Masimo's own watch."

Masimo said Apple's patent lawsuit was "retaliatory" and "an attempt to avoid the court in which the parties have been litigating their dispute."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.